Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy

HIV Clinical Trials

Volumn 11, Issue 6, 2010, Pages 303-311

  Floridia, Marco ^a   Ravizza, Marina ^b   Pinnetti, Carmela ^c   Tibaldi, Cecilia ^d   Bucceri, Anna ^e   Anzidei, Gianfranco ^f   Fiscon, Marta ^g   Molinari, Atim ^h   Martinelli, Pasquale ⁱ   Dalzero, Serena ^b   Tamburrini, Enrica ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

antiretroviral treatment; HIV; pregnancy; viral load; women

Indexed keywords

DIDANOSINE; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LOGISTIC MODELS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; RISK FACTORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 78751530312     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1106-303     Document Type: Article

References (16)

1. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodefi ciency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402.
2. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defi c Syndr. 2005;38:87-95.
3. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States - May 24, 2010. Guidelines/ GuidelineDetail.aspx?MenuItem=Guidelines&Se arch=Off&GuidelineID= 9&ClassID=2. Accessed September 8, 2010.
4. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;1 :CD003510.
5. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-tochild HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008;22:289-299.
6. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22:973-981.
7. Galli L, Puliti D, Chiappini E, et al. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? Clin Infect Dis. 2009;48:1310-1317.
8. Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defi c Syndr. January 8, 2010. [Epub ahead of print]
9. Girardi E, Vanacore P, Costa F, et al. Trends in HIV prevalence among pregnant women in Italy, 1994 to 2002. J Acquir Immun Defi c Syndr. 2006;41:361-364.
10. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1despite a maternal viral load <500 copies/ml at delivery: A case-control study nested in the french perinatal cohort EPF-ANRS CO1 Clin. Infect Dis. 2010 50 585-596
11. European Collaborative Study. Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception. Antivir Ther. 2010;15:41-49.
12. Floridia M, Tamburrini E, Ravizza M, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther. 2006;11:941-946.
13. 4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy. Antivir Ther. 2008;13:519-527.
14. Fernández-Ibieta M, Ramos Amador JT, Guillén Martín S, et al. Why are HIV-infected infants still being born in Spain? Ann Pediatr (Barc). 2007;67:109-115.
15. Macassa E, Burgard M, Veber F, et al. Characteristics of HIV-infected children recently diagnosed in Paris, France. Eur J Pediatr. 2006;165:684-687.
16. The National Program on Surveillance on Antiretroviral Treatment in Pregnancy. 17th Periodical Study Report. Submitted to Ethics Committee. June 11, 2010.